DexCom Inc. (DXCM) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
DexCom’s revenue went from $573M in fiscal 2016 to $4.7B in fiscal 2025, growth of about 26.2% a year.
Net income in fiscal 2025 was $836M, a net margin of 17.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $5.1B and net income $991M.
Free cash flow was $1.1B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 21% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B | $1.9B | $1.5B | $1.0B | $718M | $573M |
| Gross profit | $3.2B | $2.8B | $2.4B | $2.3B | $1.9B | $1.7B | $1.3B | $932M | $664M | $492M | $378M |
| Operating income | $1.2B | $912M | $600M | $598M | $391M | $266M | $300M | $142M | -$186M | -$42M | -$64M |
| Net income | $991M | $836M | $576M | $542M | $341M | $217M | $550M | $101M | -$127M | -$50M | -$66M |
| EPS (diluted) | $2.54 | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 | $1.33 | $0.28 | $-0.36 | $-0.15 | $-0.20 |
| R&D | $608M | $599M | $552M | $506M | $484M | $517M | $360M | $274M | $200M | $185M | $156M |
| Revenue growth | — | +15.6% | +11.3% | +24.5% | +18.8% | +27.1% | +30.5% | +43.1% | +43.6% | +25.3% | +42.6% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.4B | $1.4B | $990M | $748M | $670M | $442M | $476M | $314M | $123M | $92M | $56M |
| Capital spending | -$316M | -$364M | -$359M | -$237M | -$365M | -$389M | -$199M | -$180M | -$67M | -$66M | -$56M |
| Free cash flow | $1.1B | $1.1B | $631M | $512M | $305M | $53M | $277M | $134M | $56M | $26M | $500000 |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $1.3B | $500M | $750M | $689M | $558M | $0 | $0 | $0 | $100M | $0 | $0 |
| Stock-based pay | $154M | $160M | $170M | $151M | $126M | $113M | $119M | $103M | $102M | $106M | $111M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $918M | $2.3B | $2.7B | $2.5B | $2.4B | $818M | $446M | $1.2B | $549M | $124M |
| Debt | — | $95M | $1.3B | $101M | $888M | $119M | $118M | $86M | $40M | $0 | — |
| Equity | — | $2.7B | $2.1B | $2.1B | $2.1B | $2.0B | $1.6B | $883M | $663M | $419M | $284M |
| Total assets | — | $6.3B | $6.5B | $6.3B | $5.4B | $4.9B | $4.3B | $2.4B | $1.9B | $904M | $403M |
| Shares (diluted) | 384M | 406M | 413M | 426M | 428M | 429M | 420M | 369M | 353M | 345M | 334M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 63.4% | 60.1% | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% | 63.1% | 64.4% | 68.5% | 66.0% |
| Operating margin | 24.0% | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | 15.5% | 9.6% | -18.1% | -5.9% | -11.2% |
| Net margin | 19.4% | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | 28.5% | 6.9% | -12.3% | -7.0% | -11.4% |
| FCF margin | 21.5% | 23.1% | 15.6% | 14.1% | 10.5% | 2.2% | 14.4% | 9.1% | 5.4% | 3.6% | 0.1% |
| ROIC | — | 24.7% | 14.4% | 21.0% | 11.3% | 10.4% | 14.2% | 14.2% | -20.9% | -8.0% | -17.8% |
| ROE | — | 30.5% | 27.4% | 26.2% | 16.0% | 10.6% | 35.4% | 11.5% | -19.2% | -12.0% | -23.1% |
Frequently asked questions
What is DexCom’s annual revenue?
$4.7B in fiscal 2025 and $5.1B over the twelve months to September 30, 2026.
How much profit does DexCom make?
Net income was $836M in fiscal 2025 (net margin 17.9%).
Is DexCom’s revenue growing?
Yes: revenue rose 15.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.